Published in Anticancer Drugs on October 01, 1998
Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci U S A (1999) 1.55
The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr J (2007) 0.96
Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer. BMC Cancer (2002) 0.95
The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer (2004) 0.93
Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer. Am J Pathol (2001) 0.89
Quantitative detection of promoter hypermethylation as a biomarker of acute kidney injury during transplantation. Transplant Proc (2006) 0.85
Methylation analysis of the glypican 3 gene in embryonal tumours. Br J Cancer (2004) 0.85
A modified protocol for bisulfite genomic sequencing of difficult samples. Biol Proced Online (2009) 0.76
Downregulation of retinoic acid receptor-beta(2) expression is linked to aberrant methylation in esophageal squamous cell carcinoma cell lines. World J Gastroenterol (2004) 0.75
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 2.99
Risk of childhood leukemia associated with exposure to pesticides and with gene polymorphisms. Epidemiology (1999) 2.85
Partial purification and properties of two forms of deoxyribonucleic acid polymerase from calf thymus. J Biol Chem (1973) 2.31
Effect of cytosine arabinoside 5'-triphosphate on mammalian DNA polymerase. Biochem Biophys Res Commun (1969) 2.16
Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res (1976) 1.70
Reverse transcriptase activity from human embryonal carcinoma cells NTera2D1. EMBO J (1990) 1.68
The gene for incontinentia pigmenti is assigned to Xq28. Genomics (1989) 1.52
A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine. Cancer Res (1974) 1.48
Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood (1999) 1.45
Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer (2003) 1.44
Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol (1983) 1.37
Genetic characterisation of Toxoplasma gondii in wildlife from North America revealed widespread and high prevalence of the fourth clonal type. Int J Parasitol (2011) 1.30
Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol (1983) 1.24
FISH ordering of reference markers and of the gene for the alpha 5 subunit of the gamma-aminobutyric acid receptor (GABRA5) within the Angelman and Prader-Willi syndrome chromosomal regions. Hum Mol Genet (1993) 1.22
Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res (1983) 1.19
Evolution of mouse B1 repeats: 7SL RNA folding pattern conserved. J Mol Evol (1991) 1.16
High intensity focused ultrasound--a surgical technique for the treatment of discrete liver tumours. Phys Med Biol (1989) 1.15
Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol (1993) 1.15
Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. Leuk Res (1981) 1.15
Risk of childhood leukemia associated with diagnostic irradiation and polymorphisms in DNA repair genes. Environ Health Perspect (2000) 1.13
Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer (2000) 1.10
Use of gamma irradiation to eliminate DNA contamination for PCR. Nucleic Acids Res (1990) 1.09
Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine. Pharmacol Ther (1985) 1.08
Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol (1992) 1.07
Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther (1985) 1.07
Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem (1968) 1.06
Antibiotic prophylaxis for post-operative wound infection in clean elective breast surgery. Eur J Surg Oncol (2000) 1.05
Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res (1984) 1.04
In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine. Cancer Res (1977) 1.04
Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol (2001) 1.03
Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. Cancer Res (1983) 1.03
High resolution deletion mapping reveals frequent allelic losses at the DNA mismatch repair loci hMLH1 and hMSH3 in non-small cell lung cancer. Int J Cancer (1998) 1.03
Kinetic and template studies with 1- -D-arabinofuranosylcytosine 5'-triphosphate and mammalian deoxyribonucleic acid polymerase. Mol Pharmacol (1972) 1.03
The human gamma-aminobutyric acid receptor subunit beta 3 and alpha 5 gene cluster in chromosome 15q11-q13 is rich in highly polymorphic (CA)n repeats. Genomics (1994) 1.01
DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine. Anticancer Drugs (1999) 1.01
Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside. Biochim Biophys Acta (1968) 1.01
Allelic loss in childhood acute lymphoblastic leukemia. Leuk Res (1997) 1.01
Monophyletic origin of Alu elements in primates. J Mol Evol (1998) 1.00
Dinucleotide repeat polymorphism at the GABAA receptor alpha 5 (GABRA5) locus at chromosome 15q11-q13. Hum Mol Genet (1992) 1.00
Mutational and expression analysis of the chromosome 12p candidate tumor suppressor genes in pre-B acute lymphoblastic leukemia. Leukemia (2004) 1.00
Mammalian deoxynucleoside kinases. II. Deoxyadenosine kinase: purification and properties. J Biol Chem (1971) 0.99
Linkage studies do not confirm the cytogenetic location of incontinentia pigmenti on Xp11. Hum Genet (1988) 0.99
Linkage mapping by simultaneous screening of multiple polymorphic loci using Alu oligonucleotide-directed PCR. Proc Natl Acad Sci U S A (1992) 0.99
Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer (2001) 0.99
Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay. Anal Biochem (1999) 0.97
Kinetics of phosphorylation of 5-aza-2'-deoxyycytidine by deoxycytidine kinase. Biochem Pharmacol (1979) 0.97
Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine. Leuk Res (1985) 0.97
Preconceptional paternal exposure to pesticides and increased risk of childhood leukaemia. Lancet (1999) 0.96
Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol (1984) 0.95
High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine. J Pharm Sci (1981) 0.94
Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol (1998) 0.93
Colorectal breast metastases presenting with atypical imaging features. Br J Radiol (2008) 0.93
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2009) 0.90
Parental smoking, CYP1A1 genetic polymorphisms and childhood leukemia (Québec, Canada). Cancer Causes Control (2000) 0.90
Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res (1994) 0.90
Frequent loss of heterozygosity at the DNA mismatch-repair loci hMLH1 and hMSH3 in sporadic breast cancer. Br J Cancer (1999) 0.90
Expression of 2 variant forms of fibroblast growth factor receptor 1 in human breast. Int J Cancer (1995) 0.90
Insulin modulation of newly synthesized apolipoproteins B-100 and B-48 in human fetal intestine: gene expression and mRNA editing are not involved. FEBS Lett (1996) 0.88
Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev (2000) 0.87
Single-strand conformational polymorphisms (SSCP): detection of useful polymorphisms at the dystrophin locus. Hum Genet (1992) 0.87
Human gamma-aminobutyric acid-type A receptor alpha5 subunit gene (GABRA5): characterization and structural organization of the 5' flanking region. Genomics (1997) 0.87
Activation of the retinoic acid receptor beta gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs (1997) 0.86
Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus. Cancer Res (1974) 0.85
Microsatellite instability in childhood T cell acute lymphoblastic leukemia. Leukemia (1997) 0.85
Methylation analysis of the glypican 3 gene in embryonal tumours. Br J Cancer (2004) 0.85
Detection of a mutator phenotype in cancer cells by inter-Alu polymerase chain reaction. Cancer Res (1996) 0.84
Iron-ascorbic acid-induced oxidant stress and its quenching by paraoxonase 1 in HDL and the liver: comparison between humans and rats. J Cell Biochem (2005) 0.84
Association between genetic variants in the HNF4A gene and childhood-onset Crohn's disease. Genes Immun (2012) 0.83
Sample preparation for the determination of 5-aza-2'-deoxycytidine in plasma by high-performance liquid chromatography. J Chromatogr (1985) 0.83
Studies on the phosphorylation of cytosine arabinoside in mammalian cells. Mol Pharmacol (1971) 0.83
Effects of 5-aza-2'-deoxycytidine on survival and cell cycle progression of L1210 leukemia cells. Leuk Res (1986) 0.83
A new atypical highly mouse virulent Toxoplasma gondii genotype isolated from a wild black bear in Alaska. J Parasitol (2010) 0.83
Frequent deletion of chromosome 12p12.3 in children with acute lymphoblastic leukaemia. Br J Haematol (1997) 0.83
Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia. Cancer Treat Rep (1984) 0.83
Effect of DNA polymerase on nuclei from different phases of cell cycle. Eur J Biochem (1974) 0.82
Comparative analysis of the ETV6 gene in vertebrate genomes from pufferfish to human. Oncogene (2001) 0.82
Genomic loci susceptible to replication errors in cancer cells. Br J Cancer (1998) 0.82
Mammalian deoxynucleoside kinases. IV. Deoxythymidine kinase: purification, properties, and kinetic studies. J Biol Chem (1971) 0.81
Mammalian deoxynucleoside kinases. 3. Deoxyadenosine kinase: inhibition by nucleotides and kinetic studies. J Biol Chem (1971) 0.81
Paraoxonase 1, 2 and 3 DNA variants and susceptibility to childhood inflammatory bowel disease. Gut (2006) 0.81
Overall informativity, OI, in DNA polymorphisms revealed by inter-Alu PCR: detection of genomic rearrangements. Genomics (1996) 0.81
Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res (1995) 0.81
Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene. Cancer Gene Ther (2001) 0.81
Toxicology in mice of the antileukemic agent 5-aza-2'-deoxycytidine. Drug Chem Toxicol (1981) 0.80
Childhood acute lymphoblastic leukemia: genetic determinants of susceptibility and disease outcome. Rev Environ Health (2002) 0.80
Chromosomal assignment of loci susceptible to replication errors by radiation hybrid mapping. Mutat Res (1998) 0.80
Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Anticancer Drugs (1991) 0.80
Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes. J Viral Hepat (2006) 0.80
5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leuk Res (1984) 0.80
Interaction of retinoic acid and vitamin D3 analogs on HL-60 myeloid leukemic cells. Leuk Res (1993) 0.80
Fine physical and transcript mapping of a 1.8 Mb region spanning the locus for childhood acute lymphoblastic leukemia on chromosome 12p12. 3. Gene (1999) 0.79
The regulatory properties of deoxyadenosine kinase. Biochim Biophys Acta (1968) 0.79
Allelic losses and DNA methylation at DNA mismatch repair loci in sporadic colorectal cancer. Carcinogenesis (1998) 0.79
Kinetic studies with 5-azacytidine-5'-triphosphate and DNA-dependent RNA polymerase. Biochem Pharmacol (1977) 0.79
Effect of tRNA from 5-azacytidine-treated hamster fibrosarcoma cells on protein synthesis in vitro in a cell-free system. Biochem Pharmacol (1976) 0.79
Increased sensitivity to a vitamin D3 analog in HL-60 myeloid leukemic cells resistant to all-trans retinoic acid. Leukemia (1994) 0.79
Inhibition of cytotoxic action of 1- -D-arabinofuranosylcytosine on S-phase HeLa cells by 5-fluorodeoxyuridine. Cancer Res (1973) 0.79
Kinetic interaction of 5-AZA-2'-deoxycytidine-5'-monophosphate and its 5'-triphosphate with deoxycytidylate deaminase. Mol Pharmacol (1984) 0.79
Asymmetrical regulation of scavenger receptor class B type I by apical and basolateral stimuli using Caco-2 cells. J Cell Biochem (2007) 0.78